Early Detection of Pancreatic Cancer

  • Vasco Eguia Division of Digestive and Liver Diseases, Columbia University Medical Center. New York, NY, USA
  • Tamas Adam Gonda Division of Digestive and Liver Diseases, Columbia University Medical Center. New York, NY, USA
  • Muhammad Wasif Saif Divisions of Hematology and Oncology, Columbia University Medical Center. New York, NY, USA
Keywords: Antibodies, Neoplasm, Carcinoma, Pancreatic Ductal, Early Detection of Cancer



Despite treatment advances pancreatic cancer remains one of the most lethal malignancies. It is expected that early detection and screening of high risk patient population may have the most significant impact on altering overall survival in this disease. Serologic biomarkers may be the most useful in early detection and histology-based markers may have the most significant role in differentiating benign, pre-malignant and malignant lesions. Here we review several serum and tissue-based biomarkers and summarize new data presented at the 2012 ASCO Gastrointestinal Cancers Symposium (Abstracts #151, #164, #188) on the potential role of PAM4 in pancreatic cancer screening and diagnosis.



Download data is not yet available.


Jemal A, Murray T, Ward E. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.

Yeo CJ, Cameron JL, Lillemoe KD. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg 1995;221:721-31.

McSweeney SE, O'Donoghue PM, Jhaveri K Current and emerging techniques in gastrointestinal imaging. J Postgrad Med 2010; 56:109-116

Galasso D, Carnuccio A, Larghi A Pancreatic cancer: diagnosis and endoscopic staging. Eur Rev Med Pharmacol Sci 2010; 14:375-385

Bunger S, Lauber T, Roblick UJ, Habermann JK. Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol 2011;137:375-389

Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004; 13:487-91. [PMID 15006928]

Jiang JT, Wu CP, Deng HF, Lu MY, Wu J, Zhang HY, et al. Serum level of TSGF, CA242 and CA 19-9 in pancreatic cancer. World J Gastroenterol 2004; 10:1675-7. [PMID 15162550]

Yiannakou JY, Newland P, Calder F, Kingsnorth AN, Rhodes JM. Prospective study of CAM 17.1/WGA mucin assay for serological diagnosis of pancreatic cancer. Lancet 1997; 349:389-92. [PMID 9033465]

Simeone DM, Ji B, Banerjee M, Arumugam T, Li D, Anderson MA, et al. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 2007; 34:436-43. [PMID 17446843]

Takayama R, Nakagawa H, Sawaki A, et al. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma. J Gastroenterol 2010;45:52-59.

Fong d, Spizzo G, Gostner JM, et al. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol 21:186-191.

Varga M, Obrist P, Schneeberger S. et al. Overespression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 10:3131-3136.

Fong D, Moser P, Krammel C, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. British Journal of Cancer 2008;99:1290-1295.

Bausch D, Thomas S, Mino-Kenudson M, et al. Plectin-1 as a novel biomarker for pancreatic cancer. Clin Cancer Res 2011;17(2):302-309.

Gold DV, Goggins M, Modrak D, et al. Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Pref; 19(11);2786-94.

Gold DV,Lew K, Maliniak R, Hernandez M, Cardillo T. Characterization of monoclonal antibody PAM4 reactive with a pancreatic cancer mucin. Int J Cancer. 1994 Apr 15;57(2):204-10.

Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res. 2007 Dec 15;13(24):7380-7.

Gold DV, Gaedcke J, Ghadimi BM, Goggins M, Hruban RH, Liu M, et al. Detection of early-stage pancreatic ductal adenocarcinoma (PDAC): Sensitivity, specificity, and discriminatory properties of the serum-based PAM4-immunoassay. J Clin Oncol 30, 2012 (suppl 4; abstr 151)

Gold DV, Gaedcke J, Ghadimi BM, Goggins M, Hruban RH, Liu M, et al. Combination of the PAM4 and CA19-9 biomarkers to improve the detection of pancreatic adenocarcinoma. J Clin Oncol 30, 2012 (suppl 4; abstr 164)

Shi C, Goldenberg DM, Gold DV. Use of the monoclonal antibody PAM4 to differentiate pancreatic ductal adenocarcinoma (PDAC) from chronic pancreatitis and benign nonmucinous cysts of the pancreas. J Clin Oncol 30, 2012 (suppl 4; abstr 188)

No image available
How to Cite
EguiaV., GondaT., & SaifM. (2012). Early Detection of Pancreatic Cancer. JOP. Journal of the Pancreas, 13(2), 131-134. https://doi.org/10.6092/1590-8577/729
Highlights from the “2012 ASCO Gastrointestinal Cancers Symposium”. San Francisco, CA, USA. January 19-21, 2012